This legislation, known as the Infant Formula Safety Modernization Act of 2026, aims to significantly enhance the safety of infant formula by amending the Federal Food, Drug, and Cosmetic Act. It mandates that infant formula manufacturers conduct standardized pathogen and microorganism testing of both their manufacturing facilities and finished infant formula products. The bill requires the Food and Drug Administration (FDA) to develop a list of specific pathogens, including *Clostridium botulinum*, for which testing is required, and to specify recommended frequencies for environmental testing in critical areas like Zones 2 and 3 of facilities. A key provision requires manufacturers to provide written notification to the Secretary within one business day of any positive test result for a specified pathogen or microorganism in infant formula, even if the product has not left their control. Furthermore, the bill mandates that the FDA Commissioner establish clear and consistent inspection and compliance standards for all infant formula products, irrespective of their country of origin. To ensure greater transparency and oversight, the Secretary is also required to notify appropriate Congressional committees within one business day of receiving such positive test notifications or issuing an "official action indicated" classification following a facility inspection.